country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-180260

Copy Link Print Information

Anticancer agent 289

Anticancer agent 289 is a H₂O₂-responsive anticancer prodrug. Anticancer agent 289 exhibits H₂O₂-inducible DNA-alkylating activity, selectively inhibits the proliferation of high ROS-expressing cancer cells over nonmalignant cells, markedly suppresses tumor growth without observable toxicity in vivo. Anticancer agent 289 can be used for triple-negative breast cancer (TNBC) research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₁₂H₁₈BCl₂NO₂
Molecular Weight:289.99

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (276 KB)

Anticancer agent 289 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Anticancer agent 289 (compound 10a) (0-200 μM, 48 h) exhibits preferential cytotoxicity toward MDA-MB-468 cells with an IC₅₀ of 5.1 μM but MCF-10A cells with a 3-fold higher IC₅₀ of 16.2 μM^[1].
Anticancer agent 289 has a good aqueous solubility (74 μM) and moderate permeability (logPe =−5.67) at at physiological pH7.4, enhances a passive diffusion under acidic conditions (a modest increase (logPe =−5.22) at pH 6.4)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MDA-MB-468 and MCF-10A cells
Concentration:

0.049, 0.098, 0.195, 0.391, 0.781, 1.563, 3.125, 6.250, 12.5, 25, 50, 100 and 200 μM
Incubation Time:

48 h
Result:

Exhibited significant growth inhibition in MDA-MB-468cells,with an IC₅₀ of 5.1 μM.
Observed a 3-fold higher IC₅₀ of 15.2 μM.

In Vivo

Anticancer agent 289 (compound 10a) (5.0 mg/kg, i.p. daily for 8 weeks) selectively suppresses tumor growth while sparing normal tissues and has an antitumor activity with a favorable safety profile in a MDA-MB-468 cells-induced xenograft mice model^[1].
Anticancer agent 289 (15 mg/kg, i.p., once) has favorable safety profile, minimizing off-target effects when combination with the precisely deuterated analogue in a MDA-MB-468 cells-induced xenograft mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MDA-MB-468 cells (7.5×10⁶) induced-female nude mice (8 weeks)^[1]
Dosage:

5.0 mg/kg
Administration:

i.p. daily for 7 weeks
Result:

Displayed significantly suppressed tumor growth approximately 11%.
Has a tumor growth inhibition rate (IR) value of 89%.
Inhibits tumor weights.
Caused no treatment-related mortality or adverse effects occurred, and steadily increased body weights.
Revealed no structural abnormalities or pathological changes (including liver, kidneys, spleen, lungs, heart).

Animal Model:

MDA-MB-468 cells (2 × 10⁶) induced-female nude mice (8 weeks)^[1]
Dosage:

15 mg/kg
Administration:

i.p., once
Result:

Revealed the presence of phase II metabolites, arising from glucuronidation of phenolic intermediates and exhibit a diagnostic M/M+5 isotopic pattern substrates for UDP-glucuronosyltransferase (UGT)-catalyzed conjugated with uridine diphosphate glucuronic acid.

Chemical Information

Molecular Weight 289.99
Formel C₁₂H₁₈BCl₂NO₂
SMILES

CCC1=CC(N(CCCl)CCCl)=CC=C1B(O)O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Saxon E, et al.Precision Deuteration in Search of In Vivo Metabolites, and Activation Pathway. J Med Chem. 2025 Dec 11;68(23):25026-25037. H [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen